Predictive Values of Preoperative Prognostic Nutritional Index and Systemic Immune-Inflammation Index for Long-Term Survival in High-Risk Non-Muscle-Invasive Bladder Cancer Patients: A Single-Centre Retrospective Study.

Bacillus Calmette-Guerin cancer-specific survival non-muscle-invasive bladder cancer overall survival prognostic nutritional index systemic immune-inflammation index

Journal

Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700

Informations de publication

Date de publication:
2020
Historique:
received: 21 04 2020
accepted: 26 08 2020
entrez: 16 10 2020
pubmed: 17 10 2020
medline: 17 10 2020
Statut: epublish

Résumé

This study aimed to investigate the associations between the preoperative prognostic nutritional index (PNI), systemic immune-inflammation index (SII) and overall survival (OS) and cancer-specific survival (CSS) in high-risk non-muscle-invasive bladder cancer (NMIBC) patients who received intravesical instillation of Bacillus Calmette-Guerin (BCG) after transurethral resection of bladder tumour (TURBT). We retrospectively collected data from 387 high-risk NMIBC patients between January 2004 and December 2014. PNI was calculated as total lymphocyte count (10 The patients were divided into two groups according to the cutoff values of PNI (<50.17 vs ≥50.17) and SII (<467.76 vs ≥467.76). Kaplan-Meier analysis revealed that low PNI and high SII were associated with poorer OS and CSS in high-risk NMIBC patients. Univariate and multivariate Cox regression analyses revealed that PNI and SII were independent predictive factors for OS and CSS. Kaplan-Meier analysis also revealed that low PNI and high SII were related to poorer OS and CSS in highest-risk NMIBC patients. These results suggest that preoperative PNI and SII, based on standard laboratory measurements, may be useful noninvasive, inexpensive and simple tools for predicting the long-term survival of high-risk NMIBC patients who received intravesical instillation of BCG after TURBT.

Identifiants

pubmed: 33061634
doi: 10.2147/CMAR.S259117
pii: 259117
pmc: PMC7534864
doi:

Types de publication

Journal Article

Langues

eng

Pagination

9471-9483

Informations de copyright

© 2020 Bi et al.

Déclaration de conflit d'intérêts

The authors report grants from Beijing Municipal People’s Government, during the conduct of the study; and grants from Beijing Municipal People’s Government, outside the submitted work. The authors declare that there are no other conflicts of interest in this study.

Références

Trends Immunol. 2009 Nov;30(11):522-30
pubmed: 19775938
J Cancer Res Clin Oncol. 2017 Jul;143(7):1235-1242
pubmed: 28243747
World J Urol. 2019 Jan;37(1):155-163
pubmed: 29905887
Asian Pac J Cancer Prev. 2019 Mar 26;20(3):863-868
pubmed: 30912405
World J Oncol. 2018 Jun;9(3):85-90
pubmed: 29988766
Mol Cancer Res. 2006 Apr;4(4):221-33
pubmed: 16603636
Eur Urol. 2017 Jan;71(1):96-108
pubmed: 27370177
Eur Urol. 2016 Jan;69(1):60-9
pubmed: 26210894
Medicine (Baltimore). 2019 Feb;98(6):e14420
pubmed: 30732196
PLoS One. 2018 Nov 29;13(11):e0208267
pubmed: 30496283
J Nippon Med Sch. 2017;84(5):224-230
pubmed: 29142183
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Oncotarget. 2017 Feb 21;8(8):12891-12901
pubmed: 28039452
Eur Urol. 2019 Nov;76(5):639-657
pubmed: 31443960
J Transl Med. 2019 Jan 18;17(1):30
pubmed: 30658662
J Gastrointest Oncol. 2019 Oct;10(5):965-978
pubmed: 31602335
J Immunother Cancer. 2018 Jul 16;6(1):74
pubmed: 30012216
HPB (Oxford). 2017 Aug;19(8):695-705
pubmed: 28479010
PLoS One. 2018 Jul 26;13(7):e0200936
pubmed: 30048474
Rev Invest Clin. 2018;70(3):121-125
pubmed: 29943772
BJU Int. 2018 Apr;121(4):549-557
pubmed: 28990272
In Vivo. 2018 May-Jun;32(3):663-667
pubmed: 29695576
Bladder Cancer. 2018 Jan 20;4(1):121-128
pubmed: 29430512
J Cancer. 2016 Jan 01;7(2):131-5
pubmed: 26819635
Nutr Cancer. 2016 Oct;68(7):1108-14
pubmed: 27485861
Int J Mol Sci. 2018 Feb 02;19(2):
pubmed: 29393886
Carcinogenesis. 2009 Jul;30(7):1073-81
pubmed: 19468060
Front Pharmacol. 2016 Oct 13;7:376
pubmed: 27790145
PLoS One. 2015 Sep 10;10(9):e0136897
pubmed: 26356222
Ann Surg Oncol. 2016 Jan;23(1):321-7
pubmed: 26045392
J Cell Physiol. 2001 Nov;189(2):197-206
pubmed: 11598905
Onco Targets Ther. 2017 Nov 21;10:5541-5550
pubmed: 29200869
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
World J Gastroenterol. 2015 May 21;21(19):5961-71
pubmed: 26019461
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Ann Transl Med. 2019 Sep;7(18):431
pubmed: 31700867
Eur J Surg Oncol. 2018 May;44(5):566-570
pubmed: 29530345
Immunol Invest. 2003 Aug;32(3):201-15
pubmed: 12916709
Nutr Clin Pract. 2017 Oct;32(5):578-586
pubmed: 28633000
Breast Cancer Res. 2017 Jan 5;19(1):2
pubmed: 28057046
Surg Today. 2017 Aug;47(8):986-993
pubmed: 28315008
World J Urol. 2017 Feb;35(2):261-270
pubmed: 27255479
Cell Physiol Biochem. 2018;46(4):1595-1605
pubmed: 29694985
Eur J Clin Nutr. 2018 Sep;72(9):1255-1259
pubmed: 30185853
Lancet Oncol. 2014 Oct;15(11):e493-503
pubmed: 25281468
Pancreatology. 2015 Jul-Aug;15(4):327-30
pubmed: 25975490
ScientificWorldJournal. 2013 Mar 31;2013:703579
pubmed: 23606819

Auteurs

Huifeng Bi (H)

Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China.
Department of Urology, Jincheng General Hospital, Jincheng, Shanxi Province, People's Republic of China.

Zhenhua Shang (Z)

Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China.

Chunsong Jia (C)

Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China.

Jiangtao Wu (J)

Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China.

Bo Cui (B)

Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China.

Qi Wang (Q)

Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China.

Tongwen Ou (T)

Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China.

Classifications MeSH